Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% – Still a Buy?

by · The Markets Daily

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) shares shot up 5.2% during trading on Thursday . The company traded as high as $3.42 and last traded at $3.42. 1,043,397 shares were traded during mid-day trading, a decline of 39% from the average session volume of 1,719,907 shares. The stock had previously closed at $3.25.

Analyst Ratings Changes

XERS has been the topic of several research analyst reports. Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Monday, November 11th. HC Wainwright increased their target price on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research note on Monday, November 11th.

View Our Latest Stock Report on XERS

Xeris Biopharma Price Performance

The stock’s 50-day moving average price is $3.24 and its 200-day moving average price is $2.77. The company has a market cap of $520.29 million, a P/E ratio of -7.76 and a beta of 2.65.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors have recently made changes to their positions in the stock. Walleye Capital LLC bought a new stake in Xeris Biopharma during the third quarter worth about $3,197,000. Renaissance Technologies LLC raised its position in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after buying an additional 342,300 shares in the last quarter. Barclays PLC lifted its holdings in shares of Xeris Biopharma by 87.8% during the 3rd quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after acquiring an additional 151,685 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after acquiring an additional 93,091 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Xeris Biopharma during the 3rd quarter worth approximately $237,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Featured Articles